10-Q: 60 Degrees Pharma Q2 2026: Revenue Up, But Losses Widen

60 Degrees Pharmaceuticals reported increased product revenue in Q2 2026, but also a significant rise in operating expenses and net loss, with substantial doubt cast on its ability to continue as a going concern.

Summary

• 60 Degrees Pharmaceuticals, Inc. (60P) filed its Form 10-Q for the quarter ended June 30, 2026.
• Product revenues increased by 105.98% to $207,898 for the three months ended June 30, 2026, compared to $100,932 in the prior year period.
• Net revenue for the quarter was $56,798, a decrease from $257,820 in the prior year, largely due to the absence of research revenues.
• Operating expenses increased significantly, with Research and Development up 158.14% to $598,653 and General and Administrative expenses up 5.94% to $1,729,247.
• The company reported a net loss of $2,264,526 for the three months ended June 30, 2026, compared to a net loss of $1,733,726 in the same period last year.
• As of June 30, 2026, the company had $1,022,606 in cash and cash equivalents, down from $1,510,065 at December 31, 2025.
• The company explicitly states substantial doubt about its ability to continue as a going concern, estimating it will have sufficient funds only through early October 2026.
• The company received a letter from the FDA objecting to marketing Australian Chestnut Extract as a dietary supplement.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's continued substantial losses, significant cash burn, and the explicit statement of substantial doubt about its ability to continue as a going concern, despite some revenue growth.

Positives

• Product revenues increased by 105.98% to $207,898 for the three months ended June 30, 2026, compared to $100,932 in the prior year period, driven by improved Arakoda supply and channel inventory build-up.
• Gross profit increased by 11.63% to $56,798 for the three months ended June 30, 2026, from $50,881 in the prior year period.
• The company regained compliance with Nasdaq's minimum bid price requirement after implementing a 1:4 reverse stock split.
• The company entered into a patent license with Florida State University for the non-prescription use of Australian Chestnut extract.
• Partnership with Runway Health commenced to expand Arakoda access for malaria prevention.

Negatives

• Net loss widened to $2,264,526 for the three months ended June 30, 2026, from $1,733,726 in the prior year period.
• Cash and cash equivalents decreased to $1,022,606 as of June 30, 2026, from $1,510,065 at December 31, 2025.
• Net cash used in operating activities increased by 63.19% to $4,973,280 for the six months ended June 30, 2026, compared to $3,047,494 in the prior year period.
• The company explicitly states substantial doubt about its ability to continue as a going concern, estimating it will have sufficient funds only through early October 2026.
• Research revenues were nil in Q2 2026, compared to $206,939 in Q2 2025, due to the completion of the USAMMDA contract.
• The FDA objected to the marketing of Australian Chestnut Extract as a dietary supplement.
• Gross margin decreased significantly from 50.41% in Q2 2025 to 27.32% in Q2 2026 due to changes in product mix and cost of revenues.
• Material weaknesses in internal control over financial reporting persist, with remediation efforts dependent on securing additional financing.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern, with estimated funds only sufficient through early October 2026.
• The company may need to raise additional capital in the near future, with no assurance of obtaining it on acceptable terms.
• Failure to maintain compliance with Nasdaq's continued listing requirements, including minimum stockholders' equity, could lead to delisting.
• The FDA has objected to the marketing of Australian Chestnut Extract as a dietary supplement.
• The company's future results are subject to substantial risks and uncertainties common to the biopharmaceutical industry, including regulatory approval, competition, and commercialization challenges.
• The company relies on a single vendor for its active pharmaceutical ingredient (API) for tafenoquine, and any cessation of supply would be disruptive.
• Exclusive relationships with distributors in Australia and Europe pose a risk if these distributors fail to perform.

Future Outlook

The company estimates it will have sufficient funds to remain viable through early October 2026, considering recent financing. However, based on current cash forecasts and planned expenditures, it does not have sufficient cash to fund its operating plan for at least the next 12 months, raising substantial doubt about its ability to continue as a going concern. Future operations will likely depend on raising additional capital through equity financings or business development transactions.

Management Comments

• Management acknowledges substantial doubt about the company's ability to continue as a going concern.
• Management plans to fund operations through third-party and related-party debt/advances, private placements, and subsequent offerings.
• Management has evaluated conditions and plans to mitigate them, concluding that these plans do not alleviate the substantial doubt about the company's ability to continue as a going concern.
• Management is continuing to evaluate its internal control environment and intends to implement remedial measures as resources become available.

Industry Context

StockSavvy.ai notes that 60 Degrees Pharmaceuticals operates in the highly competitive and capital-intensive biopharmaceutical sector, where significant investment in R&D is required, and success is contingent on regulatory approvals and market adoption. The company's focus on infectious diseases, including malaria and babesiosis, addresses critical public health needs but also involves long development cycles and high failure rates.

Comparison to Industry Standards

• The company's gross margin of 27.32% for Q2 2026 is significantly lower than the typical gross margins seen in established pharmaceutical companies, which often exceed 70-80%. This is attributed to the current product mix, cost of revenues, and the impact of discounts and rebates.
• The substantial increase in R&D expenses (158.14% year-over-year for Q2 2026) aligns with industry practices for companies advancing drug candidates through clinical trials, but the overall net loss and cash burn are concerning compared to companies with more mature product portfolios or stronger revenue streams.
• The company's reliance on frequent capital raises (ATM offerings, past equity/warrant sales) is common among early-stage biopharmaceutical companies but highlights the industry's challenge in achieving self-sustaining profitability without significant product success or strategic partnerships.

Corporate Governance

Legal Proceedings

• On May 19, 2026, the FDA notified the Company that they objected to the Company marketing the Australian Chestnut Extract as a dietary supplement.
• As of June 30, 2026, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company's operations.

Stakeholder Impact

• Shareholders: The company's going concern status and potential delisting risk due to Nasdaq listing requirements could negatively impact share value and liquidity. Continued losses and reliance on capital raises dilute existing shareholders.
• Creditors: The company's ability to meet its financial obligations is dependent on future financing, posing a risk to creditors if capital is not raised.
• Suppliers: The company's reliance on a single vendor for API and contingent purchase obligations to Piramal could be impacted by the company's financial stability.
• Employees: The uncertainty surrounding the company's going concern status may impact employee morale and job security.

Next Steps

• Continue to fund operations through third-party and related-party debt/advances, private placement of restricted securities, and issuance of stock in subsequent offerings.
• Seek additional capital to fund operations and product development.
• Continue to pursue commercial support for Arakoda and fund babesiosis clinical development programs.
• Address FDA's objection regarding Australian Chestnut Extract marketing.
• Continue efforts to remediate material weaknesses in internal control over financial reporting as resources become available.

Key Dates

Recommendation

The company's persistent net losses, significant cash burn, and explicit statement of substantial doubt about its ability to continue as a going concern, despite some revenue growth, present a high-risk investment profile. The ongoing need for capital raises and the material weaknesses in internal controls further exacerbate these concerns. While product revenue is increasing, it is not yet offsetting the escalating operating expenses, and the company's financial runway is critically short.

Keywords

pharmaceuticals, infectious diseases, malaria prevention, ARAKODA, tafenoquine, babesiosis, clinical trials, FDA